Pending FDA review and approval, research findings pave way for Akili’s EVO to become first brain training platform prescribed for ADHD

By SharpBrains | December 12, 2017

Akili Achieves Pri­ma­ry Effi­ca­cy End­point in ADHD Tri­al (MD mag­a­zine): “Boston-based Akili Inter­ac­tive has announced top-line results from the STARS-ADHD piv­otal study of its inves­ti­ga­tion­al dig­i­tal ther­a­peu­tic med­i­cine AKL-T01, in treat­ment of pedi­atric atten­­tion-deficit/hy­per­ac­­tiv­i­­ty dis­or­der (ADHD)…The dig­i­tal med­i­cine, AKL-T01, is a video game for patients to play on tablet devices. It uses the same storytelling…

Read More